Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever. Case fatality rates of filovirus disease outbreaks are among the highest reported for any human pathogen, exceeding 90% (ref. 1). Licensed therapeutic or vaccine products are not available to treat filovirus diseases. Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential. Here we show that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Biochemical, reporter-based and primer-extension assays indicate that BCX4430 inhibits viral RNA polymerase function, acting as a non-obligate RNA chain terminator. Post-exposure intramuscular administration of BCX4430 protects against Ebola virus and Marburg virus disease in rodent models. Most importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when administered as late as 48 hours after infection. In addition, BCX4430 exhibits broad-spectrum antiviral activity against numerous viruses, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. This is the first report, to our knowledge, of non-human primate protection from filovirus disease by a synthetic drug-like small molecule. We provide additional pharmacological characterizations supporting the potential development of BCX4430 as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda
Towner, J. S., Sealy, T. K., Khristova, M. L., Albariño, C. G., Conlan, S., Reeder, S. A., Quan, P.-L., Lipkin, W. I., Downing, R., Tappero, J. W., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000212 · Cited by 599
Assessment of the Risk of Ebola Virus Transmission from Bodily Fluids and Fomites
Bausch, D. G., Towner, J. S., Dowell, S. F., Kaducu, F., Lukwiya, M., Sanchez, A., Nichol, S. T., Ksiazek, T. G., & Rollin, P. E. (2007) · The Journal of Infectious Diseases · doi:10.1086/520545 · Cited by 522
A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic Fever
Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., & Huggins, J. (1998) · The Journal of Infectious Diseases · doi:10.1086/515386 · Cited by 492
Mühlberger, E., Weik, M., Volchkov, V. E., Klenk, H.-D., & Becker, S. (1999) · Journal of Virology · doi:10.1128/jvi.73.3.2333-2342.1999 · Cited by 486
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Basic Clinical and Laboratory Features of Filoviral Hemorrhagic Fever
Kortepeter, M. G., Bausch, D. G., & Bray, M. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir299 · Cited by 328
Marburg-virus disease in Kenya
Smith, D. H., Isaacson, M., Johnson, K. M., Bagshawe, A., Johnson, B. K., Swanapoel, R., Killey, M., Siongok, T., & Koinange Keruga, W. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91871-2 · Cited by 324
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease
Dye, J. M., Herbert, A. S., Kuehne, A. I., Barth, J. F., Muhammad, M. A., Zak, S. E., Ortiz, R. A., Prugar, L. I., & Pratt, W. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200409109 · Cited by 268
Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates
Hevey, M., Negley, D., Pushko, P., Smith, J., & Schmaljohn, A. (1998) · Virology · doi:10.1006/viro.1998.9367 · Cited by 262
Cited by
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Self-citationAgostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
The continued threat of emerging flaviviruses
Pierson, T. C., & Diamond, M. S. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0714-0 · Cited by 1,098
Zimmermann, P., & Curtis, N. (2020) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002660 · Cited by 1,077
Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C., Angeletti, S., Ciccozzi, M., Gallo, R. C., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02344-6 · Cited by 996
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01594 · Cited by 643
Self-citationMechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2019) · Viruses · doi:10.3390/v11040326 · Cited by 622
The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing
Snijder, E. J., Decroly, E., & Ziebuhr, J. (2016) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.08.008 · Cited by 558
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection
The PREVAIL II Writing Group (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604330 · Cited by 520
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past
Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01949 · Cited by 475
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 445
Ruzek, D., Avšič Županc, T., Borde, J., Chrdle, A., Eyer, L., Karganova, G., Kholodilov, I., Knap, N., Kozlovskaya, L., Matveev, A., et al. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.01.014 · Cited by 414
The Pathogenesis of Ebola Virus Disease
Baseler, L., Chertow, D. S., Johnson, K. M., Feldmann, H., & Morens, D. M. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100506 · Cited by 404
Agostini, M. L., Pruijssers, A. J., Chappell, J. D., Gribble, J., Lu, X., Andres, E. L., Bluemling, G. R., Lockwood, M. A., Sheahan, T. P., Sims, A. C., et al. (2019) · Journal of Virology · doi:10.1128/jvi.01348-19 · Cited by 337
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Boldescu, V., Behnam, M. A. M., Vasilakis, N., & Klein, C. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.33 · Cited by 305
Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., Huang, F., Peng, T., Zhang, J., Liu, C., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.716100 · Cited by 286
SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target
Yuan, S., Chu, H., Chan, J. F.-W., Ye, Z.-W., Wen, L., Yan, B., Lai, P.-M., Tee, K.-M., Huang, J., Chen, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08015-x · Cited by 253
Challenges and recent progress in drug discovery for tropical diseases
De Rycker, M., Baragaña, B., Duce, S. L., & Gilbert, I. H. (2018) · Nature · doi:10.1038/s41586-018-0327-4 · Cited by 229
A new threat from an old enemy: Re‑emergence of coronavirus (Review)
Docea, A., Tsatsakis, A., Albulescu, D., Cristea, O., Zlatian, O., Vinceti, M., Moschos, S., Tsoukalas, D., Goumenou, M., Drakoulis, N., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4555 · Cited by 218
“The efficacy of remdesivir (Gilead Sciences), a nucleotide analog, in inhibiting in vitro and in vivo SARS-coV-1, MERS-coV and bat coV strains that are capable to replicate in human airway epithelial cells render it a good choice for testing on newly affected cOVId-19 patients (85,101-103).”
Nucleoside analogues for the treatment of coronavirus infections
Pruijssers, A. J., & Denison, M. R. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.04.002 · Cited by 196
C-Nucleosides To Be Revisited: Miniperspective
De Clercq, E. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01157 · Cited by 195
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery
Zhu, W., Chen, C. Z., Gorshkov, K., Xu, M., Lo, D. C., & Zheng, W. (2020) · SLAS Discovery · doi:10.1177/2472555220942123 · Cited by 183
Marburg virus disease: a summary for clinicians
Kortepeter, M. G., Dierberg, K., Shenoy, E. S., & Cieslak, T. J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.07.042 · Cited by 160
“Groups of six cynomolgus macaques (Warren et al., 2014) were challenged with Marburg virus and then given twice daily IM injections of Galidesivir (15 mg/kg) 1, 24 and 48 h after challenge.”
SkipGNN: predicting molecular interactions with skip-graph networks
Huang, K., Xiao, C., Glass, L. M., Zitnik, M., & Sun, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-77766-9 · Cited by 133
Singh, A. K., Kushwaha, P. P., Prajapati, K. S., Shuaib, M., Gupta, S., & Kumar, S. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104185 · Cited by 58
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors
Capuzzi, S. J., Sun, W., Muratov, E. N., Martínez-Romero, C., He, S., Zhu, W., Li, H., Tawa, G., Fisher, E. G., Xu, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00035 · Cited by 35
Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies
Gowen, B. B., & Hickerson, B. T. (2017) · Journal of Microbiology · doi:10.1007/s12275-017-7029-8 · Cited by 26
“It was also shown to be partially effective protecting up to 60% of mice from lethal RVFV challenge and extending survival times in those that succumbed by approximately one week (Warren et al., 2014).”
Metadata
- Authors
- Warren, T. K., Wells, J., Panchal, R. G., Stuthman, K. S., Garza, N. L., Van Tongeren, S. A., Dong, L., Retterer, C. J., Eaton, B. P., Pegoraro, G., Honnold, S., Bantia, S., Kotian, P., Chen, X., Taubenheim, B. R., Welch, L. S., Minning, D. M., Babu, Y. S., Sheridan, W. P., & Bavari, S.
- Venue
- Nature
- Published
- 2014-03-02
- Volume
- 508
- Issue
- 7496
- Pages
- 402-405
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2072202424
- Cited by
- 610
- References
- 27
- FWCI
- 48.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.